Related references
Note: Only part of the references are listed.Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
Ryon P. Graf et al.
EUROPEAN UROLOGY (2022)
Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy
Heng Li et al.
EUROPEAN UROLOGY (2021)
Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate
Wan-Fu Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Transcriptional profiling of primary prostate tumor in metastatic hormonesensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A. A. Hamid et al.
ANNALS OF ONCOLOGY (2021)
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Aleix Prat et al.
LANCET ONCOLOGY (2020)
Estrogen receptor β exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity
Surendra Chaurasiya et al.
PLOS ONE (2020)
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
Michael D. Nyquist et al.
CELL REPORTS (2020)
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson et al.
JCO PRECISION ONCOLOGY (2020)
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Natalia Jimenez et al.
FRONTIERS IN ONCOLOGY (2020)
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato et al.
CANCER CELL (2019)
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
Mercedes Marin-Aguilera et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
Paul G. Corn et al.
LANCET ONCOLOGY (2019)
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Vincenza Conteduca et al.
EUROPEAN UROLOGY (2019)
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
Anis A. Humid et al.
EUROPEAN UROLOGY (2019)
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression
Helmut Bonkhoff
PROSTATE (2018)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2018)
Gene Expression Detection Assay for Cancer Clinical Use
Shavira Narrandes et al.
JOURNAL OF CANCER (2018)
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L. Pare et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas
Don L. Gibbons et al.
DEVELOPMENTAL DYNAMICS (2018)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate
Wan-fu Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer
Julia Gehrig et al.
ONCOTARGET (2017)
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Shuang G. Zhao et al.
JAMA ONCOLOGY (2017)
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2017)
Survival Outcomesin Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric
Jason T. George et al.
CANCER RESEARCH (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2016)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
Ruby Yun-Ju Huang et al.
ONCOTARGET (2015)
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
Torsten Nielsen et al.
BMC CANCER (2014)
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Java Treeview-extensible visualization of microarray data
AJ Saldanha
BIOINFORMATICS (2004)
Share Paper
